Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer-Reference-Cited by-同舟云学术

Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer

Published:2013-09 Issue:3 Volume:190 Page:850-856
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Dinney Colin P.N.¹,Fisher Mark B.¹,Navai Neema¹,O'Donnell Michael A.²,Cutler David³,Abraham Alice¹,Young Sophia³,Hutchins Beth³,Caceres Maria³,Kishnani Narendra³,Sode George³,Cullen Constance³,Zhang Guangcheng⁴,Grossman H. Barton¹,Kamat Ashish M.¹,Gonzales Marshall¹,Kincaid Michael¹,Ainslie Nancy¹,Maneval Daniel C.⁵,Wszolek Matthew F.¹,Benedict William F.⁴

Affiliation:

1. Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas

2. Department of Urology, University of Iowa, Iowa City, Iowa

3. Merck, Sharp and Dohme Corp., Upper Gwynedd, Pennsylvania, Union and Kenilworth, New Jersey, and Palo Alto, California

4. Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas

5. Halozyme Therapeutics Inc., San Diego, California

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference21 articles.

1. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials;Sylvester;J Urol,2002